Pannysylvania Magazine

(Albany, US) On October 29, 2026, DelveInsight’s “Pemphigus Vulgaris Market Insights, Epidemiology and Market Forecast – 2036” report provides comprehensive insights into the Pemphigus Vulgaris (PV) market and pipeline landscape across the 7MM. It covers marketed and emerging drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type, and examines the market drivers and barriers shaping the space.

Discover the latest drugs and treatment options in the Pemphigus Vulgaris Pipeline @ https://www.delveinsight.com/report-store/pemphigus-vulgaris-market

Key Takeaways from the Pemphigus Vulgaris Report

• In April 2026, Cabaletta Bio announced multiple upcoming presentations on manufacturing, translational, and clinical data for rese-cel at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting.

• In January 2026, Ono Pharmaceutical announced IND clearance for rese-cel to be manufactured on Cellares’ automated Cell Shuttle platform, offering potential scalability to produce rese-cel for thousands of patients per year with minimal capital investment.

• Longer-term data on rese-cel without preconditioning in non-renal systemic lupus erythematosus, lupus nephritis, and pemphigus vulgaris is expected in the second half of 2026.

• Rituximab remains the only targeted biologic approved for moderate-to-severe PV in major markets, while treatment otherwise relies on corticosteroids and off-label immunosuppressants. Rituximab biosimilars have improved access and lowered costs.

• DelveInsight’s report depicts a space where the pipeline is limited but innovative, led by an oral BTK inhibitor in Phase III and a CD19-directed CAR-T therapy in Phase I/II.

• Leading Pemphigus Vulgaris companies include Ono Pharmaceutical, Cabaletta Bio, Artiva Biotherapeutics, and others.

• Promising therapies include tirabrutinib hydrochloride (ONO-4059/VELEXBRU), resecabtagene autoleucel (rese-cel/CABA-201), AB-101 (AlloNK), and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pemphigus Vulgaris Treatment Drugs

Pemphigus Vulgaris Overview

Pemphigus vulgaris is a rare, chronic, life-threatening autoimmune blistering disease driven by pathogenic autoantibodies against desmoglein-3 and, in many cases, desmoglein-1. These autoantibodies disrupt cell-to-cell adhesion between keratinocytes, causing fragile blisters and painful erosions of the mucous membranes and skin. It occurs at 0.1 to 2.7 per 100,000 people per year, is most commonly diagnosed between ages 40 and 60, and has an estimated US prevalence of about 10 to 20 cases per million. Diagnosis combines clinical presentation, biopsy showing suprabasal acantholysis, direct immunofluorescence (the diagnostic gold standard), and serology for anti-desmoglein antibodies. Systemic corticosteroids remain the cornerstone of initial therapy, usually combined with rituximab as the preferred steroid-sparing option, with azathioprine, mycophenolate mofetil, methotrexate, and cyclophosphamide used off-label, and IVIG or plasmapheresis reserved for severe cases.

Common symptoms and complications include:

• Persistent oral ulcers

• Skin blistering and painful erosions

• Mucous membrane involvement

• Risk of severe infection

• Fluid loss in untreated disease

Pemphigus Vulgaris Emerging Drugs Profile

Tirabrutinib Hydrochloride (ONO-4059/VELEXBRU): Ono Pharmaceutical Tirabrutinib is an oral, highly selective Bruton’s tyrosine kinase (BTK) inhibitor being developed for steroid-resistant pemphigus. It aims to provide an effective oral steroid-sparing therapy by suppressing B-cell activation and autoantibody production against desmogleins. Currently, the drug is in Phase III (NCT06696716) in Japan.

Resecabtagene Autoleucel (rese-cel/CABA-201): Cabaletta Bio Rese-cel is a fully human CD19 CAR-T construct with a 4-1BB co-stimulatory domain, designed to deplete CD19-positive B cells and reset the aberrant immune response across a broad range of autoimmune diseases. It is being evaluated in the Phase I/II RESET-PV trial, including without preconditioning. Currently, the drug is in Phase I/II.

AB-101 (AlloNK): Artiva Biotherapeutics AB-101 is an allogeneic natural killer (NK) cell therapy given by intravenous infusion and acting through immunologic cytotoxicity. Currently, the drug is in Phase I for pemphigus vulgaris.

Explore groundbreaking therapies and clinical trials in the Pemphigus Vulgaris Pipeline @ Pemphigus Vulgaris Treatment Drugs

Pemphigus Vulgaris Market Drivers

• Growing adoption of rituximab biosimilars: Lower costs are widening access to B-cell-depleting therapy, particularly in cost-sensitive healthcare systems, and are expected to increase biologic use.

• Favorable rare disease environment: Orphan drug incentives, regulatory support, and rising investment in autoimmune research are encouraging innovation, including an FDA Orphan Drug Designation for DSG3-CAART.

• Unmet need for steroid-sparing therapies: Long-term corticosteroid toxicity and variable outcomes with off-label immunosuppressants drive demand for safer, targeted, durable options.

• Innovative pipeline: An oral BTK inhibitor in Phase III and CAR-T and NK cell therapies in earlier development could move management beyond chronic immunosuppression.

• Potential for durable remission: Cell therapies aim for long-term immune reset, addressing frequent relapse.

• Manufacturing scalability: Automated platforms such as Cellares’ Cell Shuttle may help cell therapies reach larger patient populations.

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pemphigus Vulgaris Market Drivers and Barriers

Pemphigus Vulgaris Market Barriers

• Very small patient population: The rarity of PV limits trial recruitment and commercial opportunity.

• Sparse pipeline: Only a few late-stage or innovative candidates are in development compared with other autoimmune disorders.

• Entrenched, low-cost standard of care: Generic corticosteroids, off-label immunosuppressants, and rituximab biosimilars set a high bar and a low price benchmark for new entrants.

• Long-term corticosteroid toxicity and relapse: These persistent challenges complicate management even with current best practice.

• Delayed diagnosis and misdiagnosis: Delays can lead to disease progression and complications.

• Early-stage development: Emerging therapies are expected to have limited near-term market impact, with uptake dependent on efficacy, safety, and durability of response.

• Complexity and cost of cell therapies: Preconditioning, manufacturing, and specialized administration may limit access.

Scope of the Pemphigus Vulgaris Report

• Coverage: 7MM (US, EU4, UK, Japan)

• Companies: As listed above

• Therapies: Tirabrutinib hydrochloride (ONO-4059/VELEXBRU), resecabtagene autoleucel (rese-cel/CABA-201), AB-101 (AlloNK), and others

• Assessment by Product Type: Mono, Combination, Mono/Combination

• Assessment by Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Pemphigus Vulgaris report today! @ Pemphigus Vulgaris Companies

Table of Contents

1. Introduction

2. Executive Summary

3. Pemphigus Vulgaris: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III): Tirabrutinib (Ono Pharmaceutical)

8. Mid Stage Products (Phase II): Rese-cel (Cabaletta Bio), Phase I/II

9. Early Stage Products (Phase I): Rese-cel (Cabaletta Bio), Phase I/II; AB-101 (Artiva Biotherapeutics)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

19. About Us

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: Send Email
Phone: 09650213330
Address:A-1 NV 89107
City: delhi
State: Indiana
Country: United States
Website: https://www.delveinsight.com/